C I Badulescu1,2, R J Marlowe3, A Piciu4,2, R Buiga5,2, O Barbos6, N I Bejinariu7, G Chereches6, E Barbus8, E A Bonci1,2, D Piciu8,2. 1. "Prof.Dr.Ion Chiricuta" Institute of Oncology, Dept.of Surgical Oncology, Cluj-Napoca, Romania. 2. "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. 3. Spencer-Fontayne Corporation, New-Jersey, United States. 4. "Prof.Dr.Ion Chiricuta" Institute of Oncology, Dept. of Medical Oncology, Cluj-Napoca, Romania. 5. "Prof.Dr.Ion Chiricuta" Institute of Oncology, Dept. of Pathology, Cluj-Napoca, Romania. 6. "Prof.Dr.Ion Chiricuta" Institute of Oncology, Dept. of Radiobiology and Tumor Biology, Cluj-Napoca, Romania. 7. Santomar Oncodiagnostic, Cluj-Napoca, Romania. 8. "Prof.Dr.Ion Chiricuta" Institute of Oncology, Dept of Nuclear Medicine, Cluj-Napoca, Romania.
Abstract
PURPOSE: Minimally invasive follicular thyroid carcinomas (MIFCs) are uncommon; literature offers limited guidance on their natural history and management. Starting January 2015 we measured circulating tumor cells (CTCs) in patients with MIFC (n=22) or benign thyroid tumors with follicular features (n=4). METHODS: In a retrospective analysis, we assessed detectability of and serial changes in CTC, compared demographic/clinical differences between CTC-positive versus CTC-negative subgroups using Student's t-test, and examined correlations between CTC status and serum thyroglobulin using Spearman's test. CTCs were quantitated via immunomagnetic separation/microscopic inspection. RESULTS: Thirteen patients (50%: 12/22 MIFC, 1/4 benign tumor) were initially CTC-positive; 3 remained CTC-positive in ≥1 subsequent measurement. CTC-positive patients had larger tumors and more frequent multifocality and vascular invasion versus CTC-negative patients (n=13). However, no tested variable differed significantly between the subgroups. After 17.2±10.5 months, neither subgroup showed evidence of disease. Significant correlation was absent (p ≥ 0.263) between CTC and Tg negativity (r = 0.243; n=13 evaluable) or initial CTC positivity and Tg positivity (r = -0.418; n=9 evaluable). CONCLUSIONS: In the studied settings, CTC measurement is feasible, has unclear clinical/outcome implications, but may provide different information versus thyroglobulin testing. Lengthier assessment is warranted in larger series.
PURPOSE: Minimally invasive follicular thyroid carcinomas (MIFCs) are uncommon; literature offers limited guidance on their natural history and management. Starting January 2015 we measured circulating tumor cells (CTCs) in patients with MIFC (n=22) or benign thyroid tumors with follicular features (n=4). METHODS: In a retrospective analysis, we assessed detectability of and serial changes in CTC, compared demographic/clinical differences between CTC-positive versus CTC-negative subgroups using Student's t-test, and examined correlations between CTC status and serum thyroglobulin using Spearman's test. CTCs were quantitated via immunomagnetic separation/microscopic inspection. RESULTS: Thirteen patients (50%: 12/22 MIFC, 1/4 benign tumor) were initially CTC-positive; 3 remained CTC-positive in ≥1 subsequent measurement. CTC-positive patients had larger tumors and more frequent multifocality and vascular invasion versus CTC-negative patients (n=13). However, no tested variable differed significantly between the subgroups. After 17.2±10.5 months, neither subgroup showed evidence of disease. Significant correlation was absent (p ≥ 0.263) between CTC and Tg negativity (r = 0.243; n=13 evaluable) or initial CTC positivity and Tg positivity (r = -0.418; n=9 evaluable). CONCLUSIONS: In the studied settings, CTC measurement is feasible, has unclear clinical/outcome implications, but may provide different information versus thyroglobulin testing. Lengthier assessment is warranted in larger series.
Authors: Sabine Riethdorf; Herbert Fritsche; Volkmar Müller; Thomas Rau; Christian Schindlbeck; Brigitte Rack; Wolfgang Janni; Cornelia Coith; Katrin Beck; Fritz Jänicke; Summer Jackson; Terrie Gornet; Massimo Cristofanilli; Klaus Pantel Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Mira Milas; Joyce Shin; Manjula Gupta; Tomislav Novosel; Christian Nasr; Jennifer Brainard; Jamie Mitchell; Eren Berber; Allan Siperstein Journal: Ann Surg Date: 2010-10 Impact factor: 12.969
Authors: Mira Milas; Peter Mazzaglia; Su-Ynn Chia; Mario Skugor; Eren Berber; Sethu Reddy; Manjula Gupta; Allan Siperstein Journal: Surgery Date: 2007-02 Impact factor: 3.982
Authors: Tomislav Novosel; Hadley E Ritter; Manjula Gupta; Adrian Harvey; Jamie Mitchell; Eren Berber; Allan Siperstein; Mira Milas Journal: Surgery Date: 2009-12 Impact factor: 3.982
Authors: Anne Bachelot; Anne Françoise Cailleux; Michele Klain; Eric Baudin; Marcel Ricard; Nicolas Bellon; Bernard Caillou; Jean Paul Travagli; Martin Schlumberger Journal: Thyroid Date: 2002-08 Impact factor: 6.568
Authors: Reza Asari; Oskar Koperek; Christian Scheuba; Philipp Riss; Klaus Kaserer; Martha Hoffmann; Bruno Niederle Journal: Ann Surg Date: 2009-06 Impact factor: 12.969
Authors: Mira Milas; German F Barbosa; Jamie Mitchell; Eren Berber; Allan Siperstein; Manjula Gupta Journal: Ann Surg Oncol Date: 2008-11-18 Impact factor: 5.344